Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Company
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo AstraZeneca PLC
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Number of employees : 76 100 people.
Sales per Business
20192020Delta
GBP (in Million)%GBP (in Million)%
Oncology6,79435.5%8,46139.3% +24.54%
Cardiovascular, Renal & Metabolism5,41328.3%5,53425.7% +2.22%
Respiratory4,22622.1%4,17719.4% -1.14%
Other Diseases2,03910.7%2,0179.4% -1.05%
Externalisation Revenue641.983.4%566.932.6% -11.69%
Sales per region
2020
GBP (in Million)%
United States6,98332.5%
China4,16819.4%
Japan2,0029.3%
United Kingdom1,3586.3%
Other Asia, Africa and Australasia1,1965.6%
Other Continental Europe1,0855%
Sweden800.093.7%
Germany730.693.4%
Other Americas593.442.8%
France509.222.4%
Managers
NameAgeSinceTitle
Pascal Soriot612012Chief Executive Officer & Executive Director
Marc Dunoyer682013Chief Financial Officer & Executive Director
Menelas Pangalos-2019EVP-Biopharmaceuticals Research & Development
Pam Cheng492015Executive VP-Operations & Information Technology
Henry Cremisi--Medical Director
Hasan Jafri--Senior Medical Director
Katarina Ageborg-2017Chief Compliance Officer & EVP-Sustainability
Marcus Wallenberg641999Independent Non-Executive Director
Leif Johansson692012Non-Executive Chairman
Philip Arthur John Broadley592021Senior Independent Non-Executive Director
Members of the board
NameAgeSinceTitle
Leif Johansson692012Non-Executive Chairman
Marcus Wallenberg641999Independent Non-Executive Director
Marc Dunoyer682013Chief Financial Officer & Executive Director
Pascal Soriot612012Chief Executive Officer & Executive Director
Philip Arthur John Broadley592021Senior Independent Non-Executive Director
Nazneen Rahman, Dr.-2017Independent Non-Executive Director
Sherilyn McCoy612017Independent Non-Executive Director
Deborah DiSanzo602017Independent Non-Executive Director
Tony Mok, Dr.592019Independent Non-Executive Director
Michel DemarÚ642019Independent Non-Executive Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,312,772,156 1,256,776,616 95.7% 0 0.0% 95.7%
Shareholders
NameEquities%
Wellington Management Co. LLP 68,525,329 5.22%
Capital Research & Management Co. (World Investors) 56,102,804 4.27%
BlackRock Investment Management (UK) Ltd. 54,582,684 4.16%
Investor AB (Investment Company) 51,587,810 3.93%
The Vanguard Group, Inc. 35,249,067 2.69%
Norges Bank Investment Management 30,235,000 2.30%
BlackRock Fund Advisors 24,893,988 1.90%
BlackRock Advisors (UK) Ltd. 17,042,861 1.30%
SSgA Funds Management, Inc. 13,584,656 1.03%
State Street Global Advisors Ltd. 12,014,420 0.92%
Holdings
NameEquities%Valuation
AstraZeneca Pharma India Limited (506820) 18,750,00075.0%974,439,750 USD
ADC Therapeutics SA (ADCT) 4,011,2155.23%86,842,805 USD
Silence Therapeutics plc (SLN) 4,397,2474.92%39,901,675 USD
Circassia Group Plc (CIR) 71,081,21717.0%34,266,122 USD
Innate Pharma S.A. (IPH) 7,485,5009.48%27,895,764 USD
Pieris Pharmaceuticals, Inc. (PIRS) 3,584,2305.66%12,329,751 USD
PhaseBio Pharmaceuticals, Inc. (PHAS) 3,004,5546.27%10,155,393 USD
Entasis Therapeutics Holdings Inc. (ETTX) 2,164,8555.80%5,130,706 USD
Company contact information
AstraZeneca Plc
Cambridge Biomedical Campus
1 Francis Crick Avenue
Cambridge, Cambridgeshire CB2 0AA

Phone : +44.20.3749.5000
Fax : +44.12.2335.2858
Web : http://www.astrazeneca.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of AstraZeneca PLC
Sector Other Pharmaceuticals
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.47%151 865
JOHNSON & JOHNSON2.92%435 090
ROCHE HOLDING AG12.75%328 768
PFIZER, INC.5.43%220 997
NOVARTIS AG2.73%210 424
ABBVIE INC.5.57%202 939
ELI LILLY AND COMPANY29.44%201 995
MERCK & CO., INC.-6.34%195 551
NOVO NORDISK A/S20.68%189 536
BRISTOL-MYERS SQUIBB COMPANY7.16%149 087
AMGEN INC.3.81%138 330
SANOFI12.95%132 466
GLAXOSMITHKLINE PLC6.07%100 085
JIANGSU HENGRUI MEDICINE CO., LTD.-23.09%70 289
CHUGAI PHARMACEUTICAL CO., LTD.-22.77%64 764
ALLERGAN PLC0.97%63 659
BAYER AG9.54%62 588
TAKEDA PHARMACEUTICAL COMPANY LIMITED-0.85%53 301
DAIICHI SANKYO COMPANY, LIMITED-28.98%44 370
ASTELLAS PHARMA INC.21.89%32 656
EISAI CO., LTD.63.80%29 630